Cytokinetics EVP sells 3,500 shares after option exercise
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik exercised 3,500 non-qualified stock options at $7.80 per share on July 21, 2026, receiving 3,500 common shares and selling the same number at $80.59 per share. The transactions, conducted under a Rule 10b5-1 trading plan, left him holding 33,886 non-qualified stock options.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 3,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,500 | $7.80 | $27K |
| Sale | Common Stock | 3,500 | $80.59 | $282K |
Key Figures
Key Terms
Non-Qualified Stock Option (Right to Buy) financial
Rule 10b5-1 regulatory
derivative security financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cytokinetics (CYTK) EVP Fady Malik report?
At what price were Cytokinetics (CYTK) stock options exercised in this Form 4?
Were the Cytokinetics (CYTK) insider transactions made under a Rule 10b5-1 plan?
How many Cytokinetics (CYTK) stock options does the EVP hold after the reported transactions?
What type of securities were involved in the Cytokinetics (CYTK) Form 4 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.